← Back to Patent Explorer
US5399347A Expired / Lapsed US ⏱️ 0.0 years remaining

Method of treating rheumatoid arthritis with type II collagen

Assignee: BRONSON NUTRITIONALS LLC
•
Filing: 1992-09-25
•
Granted: 1995-03-21
•
Expires: 2012-09-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention is directed to a method and pharmaceutical formulations for the treatment of autoimmune arthritis and animal models therefore in mammals, including humans, by the oral, enteral or by-inhalation administration of whole collagen protein or biologically active peptide fragments of collagen.

Inventors

  • 👤 David E. Trentham
  • 👤 Howard L. Weiner
  • 👤 David A. Hafler

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-08 14:21
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/1703; A61K38/1709; A61K38/39; A61K39/00; A61K39/0005; A61K39/0008; C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4713; C07K14/78; A61K2039/54; A61K2039/541; A61K2039/542; A61K2039/543

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 57 words
A method for treating rheumatoid arthritis comprising oral administration of whole collagen II protein to a human in need of treatment, in an amount effective and for a period of time sufficient to decrease at least one clinical symptom selected from the group consisting of joint tenderness, joint swelling, morning stiffness, grip strength, and 50-foot walk time.
Claim 2
Independent Claim 57 words
A method for treating rheumatoid arthritis comprising oral administration of whole collagen II protein to a human in need of treatment, in an amount effective and for a period of time sufficient to decrease at least one clinical symptom selected from the group consisting of joint tenderness, joint swelling, morning stiffness, grip strength, and 50-foot walk time.
Claim 3
Dependent Claim 19 words
The method of claim 1, wherein the amount is within the range of about 0.1 to about 1 mg/day.
Claim 4
Dependent Claim 19 words
The method of claim 2 wherein the effective amount is within the range of about 0.1 to 0.5 mg/day.
Claim 5
Dependent Claim 19 words
The method of claim 2 wherein said type II collagen is dissolved in a physiologically acceptable aqueous acidic medium.
Claim 6
Independent Claim 41 words
A method for treating rheumatoid arthritis in a human in need of such treatment comprising oral administration to said human an amount of protein consisting of whole type II collagen, said amount being effective to decrease at least one arthritis symptom.
Claim 7
Independent Claim 41 words
A method for treating rheumatoid arthritis in a human in need of such treatment comprising oral administration to said human an amount of protein consisting of whole type II collagen, said amount being effective to decrease at least one arthritis symptom.
Claim 8
Independent Claim 39 words
A method for treating rheumatoid arthritis in a human in need of such treatment comprising oral administration of whole type II collagen in an amount effective to suppress autoimmune response in at least one afflicted joint of said human.
Claim 9
Independent Claim 39 words
A method for treating rheumatoid arthritis in a human in need of such treatment comprising oral administration of whole type II collagen in an amount effective to suppress autoimmune response in at least one afflicted joint of said human.
Claim 10
Independent Claim 44 words
A method for treating rheumatoid arthritis comprising oral administration of whole collagen II protein to a human in need of such treatment, in an amount effective and for a period of time sufficient to substantially stabilize the arthritic condition while discontinuing cytotoxic drug administration.
Claim 11
Independent Claim 44 words
A method for treating rheumatoid arthritis comprising oral administration of whole collagen II protein to a human in need of such treatment, in an amount effective and for a period of time sufficient to substantially stabilize the arthritic condition while discontinuing cytotoxic drug administration.

References Cited (Backward Citations)

US4804745A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1998-03-20 1998-09-19 1999-03-21 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2002-03-20 2002-09-19 2003-03-21 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2006-03-20 2006-09-19 2007-03-21 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag